Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SmartKem Further Expands Team in Europe with Addition of Three New Recruits

Published: Monday, February 11, 2013
Last Updated: Monday, February 11, 2013
Bookmark and Share
COO and two scientists to join the Manchester team to support SmartKem’s growth plans.

SmartKem Limited has announced the appointment of three new team members in Europe. Dr. Hugh Williamson will be welcomed as Chief Operating Officer, whilst Dr. Muhammad Raza and Dr. Keith Lumbard will join as scientists at SmartKem’s dedicated chemistry synthesis labs in Manchester.

The last 12 months has seen SmartKem appoint staff in strategic locations across Asia and Europe to further strengthen its technical and commercial activities.

As SmartKem’s third senior appointment in the past six months, following the appointment of Bill Freer as Chairman in March and Gary Tam as Business Development Director in June, Dr. Williamson possesses over 30 years’ experience in the chemicals industry which will be shared in his position as Chief Operating Officer.

Previous roles have seen Dr. Williamson excel in the delivery and introduction of new chemical products at international level.

Having spent a number of years as a senior scientist at Kodak, Dr. Williamson’s global experience and proven ability to lead R&D and operations teams will be essential in supporting SmartKem’s commercialization strategy and the development of future technology.

Possessing over 40 years’ combined experience as synthetic chemists, Dr. Lumbard and Dr. Raza will be responsible for the development of next generation organic semiconductor molecules with enhanced performance to complement SmartKem’s already market-leading materials.

“Our latest recruits are another step forward in our vision to become the leading provider of high-mobility organic semiconductor materials and solutions for flexible display backplanes and organic circuits,’’ comments Steve Kelly, CEO at SmartKem.

Kelly continued, “Hugh was a natural appointment for us as Chief Operating Officer with his strong record of scaling novel organic synthesis methods into commercial processes. This further supports our strategy to maintain strong vertical integration in organic electronics - from molecule design to market application. The appointments of Keith and Muhammad as additional synthetic chemists demonstrate our commitment to develop ultra-high mobility organic semiconductors to meet future-market needs and to extend our leadership in the field. We are delighted to welcome them to the team.”

These new appointments promise to add strength, experience and expertise to the company in order to further develop its presence in the rapidly growing flexible electronics industry.

Together, the new members of the team will further support SmartKem’s mission of becoming the leading provider of, ‘p’ type organic semiconductor materials and solutions for ultra-thin and flexible electronics.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!